Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (13 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Collaboration revenue
0
0
0
41
52
Research and development
14
7
33
88
131
General and administrative
6
7
14
33
44
Total operating expenses
20
14
47
122
175
Income (loss) from operations
-20
-14
-47
-81
-124
Interest income (expense)
0
-1
-1
0
1
Loss on extinguishment of debt
0
0
-1
0
0
Other income (loss)
0
0
-1
0
0
Loss before income tax provision
-20
-15
-51
-80
-123
Income tax (benefit) provision
-1
0
0
36
-17
Net loss
-19
-15
-51
-117
-106
Add: accretion of preferred stock dividends
-7
-7
-6
0
0
Net loss attributable to common stockholders
-25
-22
-57
-117
-106
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (33 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
4
211
40
222
Available for sale securities
n/a
0
0
424
75
Due from Novartis Pharma AG
n/a
0
0
1
4
Income tax receivable
n/a
0
0
0
3
Prepaid expenses and other current assets
n/a
0
7
9
2
Total current assets
n/a
5
217
473
306
Available for sale securities
n/a
0
0
0
95
Property and equipment, net
n/a
0
0
2
3
Deferred tax assets
n/a
0
0
5
23
Security deposits
n/a
0
0
0
0
Other assets
n/a
0
0
0
0
Total assets
n/a
5
218
480
429
Liabilities and owners' equity
Accrued research and development expenses
n/a
1 1013000
2 2485000
8 7918000
19 18820000
Accounts payable and accrued expenses
n/a
1 1391000
4 3810000
9 8707000
12 12018000
Notes Payable, Current
n/a
11 11040000
0 0
0 0
0 0
Warrant liability
n/a
1 966000
0 0
0 0
0 0
Deferred revenue
n/a
0 0
0 0
3 3206000
7 6667000
Total current liabilities
n/a
14 14410000
6 6295000
20 19831000
38 37505000
Deferred revenue, long-term
n/a
0 0
0 0
206 206418000
206 206399000
Royalty purchase liability
n/a
0 0
42 41667000
125 125000000
125 125000000
Total liabilities
n/a
14 14410000
48 47962000
351 351249000
369 368904000
Temporary Equity, Carrying Amount, Attributable to Parent
n/a
114 113939000
0 0
0 0
0 0
Preferred stock
n/a
0 0
0 0
0 0
0 0
Common stock
n/a
0 1000
0 31000
0 34000
0 35000
Additional paid-in capital
n/a
0 0
353 352739000
428 428390000
466 465924000
Development Stage Enterprise, Deficit Accumulated During Development Stage
n/a
-126 -126471000
0 0
0 0
0 0
Accumulated deficit
n/a
0 0
-183 -183050000
-300 -299822000
-406 -405539000
Accumulated other comprehensive loss
n/a
0 0
0 0
0 -65000
0 -473000
Total stockholders' equity
n/a
-123 -123470000
170 169720000
129 128537000
60 59947000
Total liabilities and stockholders' equity
n/a
5 4879000
218 217682000
480 479786000
429 428851000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Jul 28, 2015 n/a restated on Feb 26, 2016 n/a restated on Aug 5, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (39 items missing)
No data available for the selected time periods
in million USD FY '11FY '12FY '13FY '14FY '15
Net loss
-19
-15
-51
-117
-106
Depreciation
0
0
0
0
1
Amortization of debt issuance costs
0
0
0
0
0
Accretion of debt discount
0
0
0
0
0
Amortization of premium and discounts on investment securities
0
0
0
2
3
Gain on sale of marketable securities
0
0
0
0
0
Non-cash change in fair value of warrant liability
0
0
1
0
0
Loss on extinguishment of debt
0
0
1
0
0
Deferred income taxes
0
0
0
0
-17
Share-based compensation
0
1
3
13
25
Series A-1, Series B-1 and Junior Preferred Stock issued for acquired technology and licenses
1
0
0
0
0
Excess Tax Benefits from Share-based Compensation
0
0
0
-4
-1
Due from Novartis Pharma AG
0
0
0
-1
-3
Prepaid expense and other current assets
0
0
-7
-2
3
Accrued interest receivable
0
0
0
0
0
Other assets
-1
1
0
0
0
Accrued research and development expenses
-1
0
1
5
11
Accounts payable and accrued expenses
0
0
2
5
3
Deferred revenue
0
0
0
210
3
Net cash (used in) provided by operating activities
-19
-13
-49
111
-79
Purchase of marketable securities
0
0
0
-598
-412
Sale of marketable securities
0
0
0
0
396
Maturities of marketable securities
3
0
0
172
266
Purchase of property and equipment
0
0
0
-2
-3
Proceeds from sale of assets
0
0
0
0
0
Net cash provided by (used in) investing activities
3
0
0
-428
248
Payment of debt issuance costs
0
0
0
0
0
Proceeds from stock option/warrant exercises
0
0
0
3
11
Proceeds from initial public offering, net
0
0
176
55
0
Excess Tax Benefits from Share-based Compensation
0
0
0
4
1
Repayment of venture debt facility, net
0
11
-12
0
0
Proceeds from issuance of preferred stock, net
15
0
50
0
0
Proceeds from royalty purchase agreement
0
0
42
83
0
Net cash provided by financing activities
15
11
255
146
13
Net change in cash and cash equivalents
-1
-2
206
-171
182
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2016 n/a
calculated values,
restated on Feb 26, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,